Ignite Creation Date:
2025-12-24 @ 12:50 PM
Ignite Modification Date:
2025-12-24 @ 12:50 PM
Study NCT ID:
NCT04167761
Status:
COMPLETED
Last Update Posted:
2024-12-20
First Post:
2019-11-15
Is Possible Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Ertugliflozin: Cardioprotective Effects on Epicardial Fat
Sponsor:
Stanford University
Organization:
Study Overview
Official Title:
Ertugliflozin: Cardioprotective Effects on Epicardial Fat
Status:
COMPLETED
Status Verified Date:
2024-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to learn if Sodium-Glucose Cotransporter 2 inhibitor (SGLT2i) medications enhance beneficial properties of epicardial adipose tissue including metabolic flexibility, insulin sensitivity, decreased cell size and reduced inflammation.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?: